Payment overview · 2025
General Payments
$1,158.71
49 reported records · 13 companies
Healthcare provider profile · identity verified
Sumitha V Panicker, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BOLINGBROOK, IL · NPI 1528279577
Verified facts
What the public records show
CMS Open Payments records show Sumitha V Panicker, M.D. received $1,158.71 in general payments during 2025 across 49 reported records.
MIMEDX Group, Inc. accounted for 26.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $310.22 | 26.8% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $245.19 | 21.2% | 14 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $138.73 | 12.0% | 7 | 2025 |
| Surgenex LLC | Unresolved — no canonical attribution shown | $126.44 | 10.9% | 4 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $62.53 | 5.4% | 2 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $47.94 | 4.1% | 2 | 2025 |
| CashFlow Solutions, LLC | Unresolved — no canonical attribution shown | $47.00 | 4.1% | 2 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $43.15 | 3.7% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.97 | 3.2% | 4 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $35.89 | 3.1% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.26 | 2.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.86 | 1.8% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $13.53 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,158.71 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $165.34 | 8 | 2025 |
Source payment records
|
|||||
| ArdeoGraft Normalized: ardeograft |
Biological | Surgenex LLC | $126.44 | 4 | 2025 |
Source payment records
|
|||||
| PelloGraft Normalized: pellograft |
Biological | Surgenex LLC | $126.44 | 4 | 2025 |
Source payment records
|
|||||
| RenoGraft Normalized: renograft |
Biological | Surgenex LLC | $126.44 | 4 | 2025 |
Source payment records
|
|||||
| SurGraft Normalized: surgraft |
Biological | Surgenex LLC | $126.44 | 4 | 2025 |
Source payment records
|
|||||
| SurMatrix Normalized: surmatrix |
Biological | Surgenex LLC | $126.44 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $79.85 | 6 | 2025 |
Source payment records
|
|||||
| V.A.C. VERAFLO CLEANSE CHOICE Normalized: v a c veraflo cleanse choice |
Device | Solventum Corporation | $62.53 | 2 | 2025 |
Source payment records
|
|||||
| Integra Normalized: integra |
Device | Integra LifeSciences Corporation | $47.94 | 2 | 2025 |
Source payment records
|
|||||
| Integra Dermal Regeneration Template Normalized: integra dermal regeneration template |
Device | Integra LifeSciences Corporation | $47.94 | 2 | 2025 |
Source payment records
|
|||||
| PRIMATRIX Normalized: primatrix |
Device | Integra LifeSciences Corporation | $47.94 | 2 | 2025 |
Source payment records
|
|||||
| LYMPHA PRESS OPTIMAL PLUS(US) BT Normalized: lympha press optimal plus us bt |
Device | CashFlow Solutions, LLC | $47.00 | 2 | 2025 |
Source payment records
|
|||||
| PCD-51 731A (US) - White Normalized: pcd 51 731a us white |
Device | CashFlow Solutions, LLC | $47.00 | 2 | 2025 |
Source payment records
|
|||||
| PCD-52 737A (US) White Normalized: pcd 52 737a us white |
Device | CashFlow Solutions, LLC | $47.00 | 2 | 2025 |
Source payment records
|
|||||
| GRAFIX PL Normalized: grafix pl |
Biological | Smith+Nephew, Inc. | $43.82 | 2 | 2025 |
Source payment records
|
|||||
| APLIGRAF Normalized: apligraf |
Device | Organogenesis Inc. | $43.15 | 2 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $42.58 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $36.97 | 4 | 2025 |
Source payment records
|
|||||
| "ACTICOAT 4"" X 4""" Normalized: acticoat 4 x 4 |
Device | Smith+Nephew, Inc. | $36.70 | 1 | 2025 |
Source payment records
|
|||||
| PICO 7 Normalized: pico 7 |
Device | Smith+Nephew, Inc. | $36.70 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $35.89 | 3 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $35.89 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $30.26 | 2 | 2025 |
Source payment records
|
|||||
| GRAFIX Normalized: grafix |
Biological | Smith+Nephew, Inc. | $15.63 | 2 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $13.53 | 1 | 2025 |
Source payment records
|
|||||
| ONZETRA XSAIL Normalized: onzetra xsail |
Drug | Currax Pharmaceuticals LLC | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 137 | 44 |
| Gentamicin Sulfate | Gentamicin Sulfate | 118 | 79 |
| Atorvastatin Calcium | Atorvastatin Calcium | 109 | 33 |
| Levothyroxine Sodium | Levothyroxine Sodium | 90 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 75 | 29 |
| Omeprazole | Omeprazole | 56 | 16 |
| Potassium Chloride | Potassium Chloride | 54 | 19 |
| Lisinopril | Lisinopril | 53 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 17 |
| Losartan Potassium | Losartan Potassium | 51 | 19 |
| Furosemide | Furosemide | 50 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 47 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 46 | 16 |
| Metformin Hcl Er | Metformin Hcl | 45 | 22 |
| Metformin Hcl | Metformin Hcl | 43 | 16 |
| Memantine Hcl | Memantine Hcl | 41 | suppressed |
| Allopurinol | Allopurinol | 40 | 13 |
| Alprazolam | Alprazolam | 40 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | suppressed |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Tradjenta | Linagliptin | 32 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | 11 |
| Gabapentin | Gabapentin | 30 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 28 | 11 |
| Eliquis | Apixaban | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Simvastatin | Simvastatin | 27 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 27 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 23 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 19 |
| Trazodone Hcl | Trazodone Hcl | 20 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Carvedilol | Carvedilol | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,158.71 · 49 records | MIMEDX Group, Inc. | "ACTICOAT 4"" X 4""", APLIGRAF, ArdeoGraft, COLLAGENASE SANTYL, CONTRAVE, GRAFIX, GRAFIX PL, Integra, Integra Dermal Regeneration Template, Kerecis GraftGuide, Kerecis SurgiClose, LYMPHA PRESS OPTIMAL PLUS(US) BT, MOUNJARO, ONZETRA XSAIL, PCD-51 731A (US) - White, PCD-52 737A (US) White, PICO 7, PRIMATRIX, PelloGraft, RenoGraft, SurGraft, SurMatrix, V.A.C. VERAFLO CLEANSE CHOICE, VOQUEZNA, ZENPEP, ZEPBOUND | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error